Source comparison
Melanotan-2 Half Life: Pharmacokinetic Comparison
Understanding where Melanotan-2 sits relative to other peptides clarifies why its dosing schedule differs so dramatically from compounds like semaglutide or CJC1295 Ipamorelin 5MG 5MG, which operate on multi-day or weekly intervals. Melanotan-2 33–60 minutes M
This comparison does not assign a generated winner or score.
- Understanding where Melanotan-2 sits relative to other peptides clarifies why its dosing schedule differs so dramatically from compounds like semaglutide or CJC1295 Ipamorelin 5MG 5MG, which operate on multi-day or weekly intervals.
- Melanotan-2
- 33–60 minutes
- MC1R/MC4R agonist; melanogenesis, appetite suppression
- Daily or every other day
- 24–72 hours (receptor-mediated)
- Cosmetic tanning, metabolic research
- Melanotan-1
- 20–30 minutes
- MC1R-selective agonist; minimal MC4R activity
- Daily during loading phase
- 24–48 hours (shorter than MT-2)
- Erythropoietic protoporphyria treatment
- Semaglutide
- ~7 days
- GLP-1 receptor agonist; insulin sensitization, gastric emptying delay
- Weekly
- 7+ days (half life matches effect)
- Type 2 diabetes, weight management
- Ipamorelin
- ~2 hours
- Growth hormone secretagogue; ghrelin receptor agonist
- Daily or twice daily
- 3–6 hours (pulsatile GH release)
- Growth hormone research protocols
- BPC-157
- ~4 hours (estimated)
- Angiogenesis, tissue repair; mechanism partially unknown
- Twice daily
- 12–18 hours
- Injury recovery, GI protection studies
- CJC-1295 (no DAC)
- ~30 minutes
- GHRH analog; pulsatile GH release
- 2–3 times daily
- 2–4 hours per pulse
- Growth hormone optimization
- Melanotan-2 half life falls into the ultra-short category alongside CJC-1295 (no DAC) and Melanotan 1, yet dosing frequency remains far lower than those comparators. The critical difference: Melanotan-2 produces prolonged receptor activation independent of plasma presence, while growth hormone secretagogues like Ipamorelin require repeated dosing to sustain pulsatile hormone release. Melanocortin receptors amplify and extend the initial signal; ghrelin receptors do not.
- Melanotan-1 shares the same receptor targets as Melanotan-2 but demonstrates higher MC1R selectivity and lower MC4R affinity. That selectivity reduces appetite suppression and erectile side effects while maintaining melanogenic potency, making it the preferred compound in clinical settings like erythropoietic protoporphyria (EPP) treatment. However, Melanotan-1's plasma half life runs even shorter—20 to 30 minutes—and its effect duration is briefer, requiring more consistent daily dosing during both loading and maintenance phases compared to Melanotan-2.
- Semaglutide represents the opposite end of the spectrum: a 7-day plasma half life that matches its effect duration almost perfectly. GLP-1 receptors don't internalize and recycle with the same persistence as melanocortin receptors, so maintaining therapeutic GLP-1 activity requires sustained plasma levels. Weekly dosing works because the peptide remains bioavailable across the entire interval—no receptor mechanism extends the effect beyond peptide presence.
- The comparison clarifies a common misconception: short half life doesn't automatically mean frequent dosing. Pharmacodynamics—how the drug affects the body—matters far more than pharmacokinetics—how the body processes the drug. Melanotan-2 half life is short, but its pharmacodynamic profile is long. Designing a dosing protocol around plasma clearance alone misses the entire mechanism.